NCT02869971View on ClinicalTrials.gov

Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

December 3, 2020

Study Completion Date

March 25, 2022

Conditions
Benign Prostatic Hyperplasia
Interventions
DEVICE

Embosphere® (Prostatic Arteries Embolization)

Prostatic Arteries Embolization with 300-500 µm trisacryl microspheres

DRUG

Drug therapy

Combodart (dutasteride 0.5 mg/tamsulosin 0.4 mg)

Trial Locations (13)

13005

AP-HM hopital la Conception, Marseille

13385

AP-HM hopital de la Timone, Marseille

33076

CHU de Bordeaux groupe hospitalier Pellegrin, Bordeaux

34295

CHU Montpellier hopital Arnaud de Villeneuve, Montpellier

CHU Montpellier hopital Lapeyronie, Montpellier

35033

CHU Rennes hopital Pontchaillou, Rennes

69310

CHU de Lyon centre hospitalier Lyon Sud, Pierre-Bénite

69437

CHU de Lyon hopital Edouard Herriot, Lyon

75010

AP-HP - Hôpital Saint-Louis, Paris

75014

AP-HP hopital Cochin, Paris

75908

AP-HP Hopital Europeen Georges Pompidou, Paris

87042

CHU de Limoges, Limoges

94010

AP-HP hopital Henri-Mondor, Créteil

All Listed Sponsors
collaborator

Ministry of Health, France

OTHER_GOV

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02869971 - Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia | Biotech Hunter | Biotech Hunter